Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BU61
UPID:
NDUF3_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BU61
Background:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3 plays a pivotal role in cellular energy production. It is crucial for the assembly of mitochondrial NADH:ubiquinone oxidoreductase complex (complex I), a key component in the mitochondrial respiratory chain that drives ATP synthesis.
Therapeutic significance:
Linked to Mitochondrial complex I deficiency, nuclear type 18, a condition with a spectrum of disorders including neurodegenerative diseases and cardiomyopathy. Understanding the role of this protein could open doors to potential therapeutic strategies for these mitochondrial disorders.